BioCentury
ARTICLE | Financial News

AcelRx, TG Therapeutics propose follow-ons

July 18, 2013 12:53 AM UTC

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) and TG Therapeutics Inc. (NASDAQ:TGTX) both announced plans late Wednesday to raise money in follow-ons. Jefferies; Piper Jaffray; and Guggenheim Securities are underwriters of AcelRx's offering. AcelRx's Zalviso (formerly Sufentanil NanoTab PCA System) is in Phase III testing to treat moderate to severe pain in a hospital setting, with an NDA submission to FDA expected this quarter. The product is a pre-programmed, handheld device that delivers a sublingual formulation of sufentanil, a synthetic opioid analgesic (see BioCentury Extra, March 5).

Roth Capital Partners; Ladenburg Thalmann; Brean Capital; and National Securities are underwriters of TG's offering. The company's ublituximab (TG-1101) is in Phase I/II testing to treat B cell lymphoid malignancies, non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The compound is a chimeric mAb against CD20. ...